Skip to content
Intellectual Property

PMPRB Guidelines and Patented Drug Pricing

The PMPRB guidelines in force since 1 January 2026 screen patented medicine prices against eleven comparator countries and inflation, then move to in-depth review only where a screen or a complaint raises concerns. The Patent Act's excessive price test and filing duties remain unchanged.

Pharmacy shelves of prescription medicines illustrating the PMPRB guidelines for patented drug pricing

Key takeaways

  • New PMPRB guidelines published on 30 June 2025 took effect on 1 January 2026.
  • Initial screening asks whether Canada's price is the highest of eleven comparator countries.
  • Price increases above the Consumer Price Index trigger closer review.
  • Complaints from approved organizations can start an in-depth review.
  • The Board can order price reductions and offsets of excess revenues after a hearing.

PMPRB guidelines in 2026: the short answer

The PMPRB guidelines that took effect on 1 January 2026 change how the Patented Medicine Prices Review Board screens the prices of patented medicines in Canada. The Board, a federal quasi-judicial body created under the Patent Act, does not set prices; it can order a rights holder to reduce a price it finds "excessive" after a hearing, and to offset excess revenues.

Under the new guidelines, published on 30 June 2025, Board staff run a two-step process: an initial or annual screening that checks whether the Canadian price is the highest among eleven comparator countries and whether price increases exceed inflation, followed by an in-depth review only where a screen raises concerns or an approved complainant files a complaint.

Pharmacy shelves of prescription medicines illustrating the PMPRB guidelines for patented drug pricing
Patented medicine prices are screened against eleven comparator countries and inflation.

For manufacturers, the 2026 regime is lighter at the screening stage than the price tests the Board used for many years, but it keeps the statutory factors, the filing obligations and the hearing power intact. Companies launching or managing patented medicines in Canada need to understand where the screens sit, what triggers deeper scrutiny, and how PMPRB review interacts with health technology assessment, pan-Canadian price negotiations and provincial listing. The Board itself has described the guidelines as a significant departure from the previous ones.

The Board's jurisdiction comes from ss. 79 to 103 of the Patent Act. The key provisions are:

  • Filing (s. 80): a rights holder for an invention pertaining to a medicine must provide the Board with information on the identity of the medicine, its prices in Canada and elsewhere, and other prescribed matters.
  • Excessive price orders (s. 83): if the Board finds, after a hearing, that a medicine is being or has been sold at an excessive price in any market in Canada, it may order the price reduced and require the rights holder to offset excess revenues, with higher remedies for a policy of excessive pricing.
  • Statutory factors (s. 85(1)): the Board must consider the prices of the medicine in the relevant market, the prices of other medicines in the same therapeutic class in that market, prices of the medicine and its class in other countries, changes in the Consumer Price Index, and any factors added by regulation.

The guidelines are not binding law. They explain how staff will monitor prices and when they will recommend that the Chairperson issue a notice of hearing. A hearing panel applies the statute, not the guidelines, although the guidelines inform expectations.

The PMPRB11 comparator countries and filing duties

The schedule to the Patented Medicines Regulations, as amended in 2019 (SOR/2019-298), lists the comparator countries for which rights holders report foreign prices: Australia, Belgium, France, Germany, Italy, Japan, the Netherlands, Norway, Spain, Sweden and the United Kingdom. This group is commonly called the PMPRB11.

Under the Regulations, price and sales information must be filed for the day the medicine is first sold in Canada, within 30 days after that day, and then for each six-month period beginning 1 January and 1 July, within 30 days after the end of the period. Information identifying the medicine and the patents must be kept up to date, with changes reported within 30 days, including the date of any additional patent term granted for patent office delay.

Practical point

The PMPRB's jurisdiction attaches when a rights holder sells a medicine to which a patent "pertains", even if the patent is not listed on the PM(NOC) register or is licensed in. Check jurisdiction as soon as any relevant patent issues, and remember that filing obligations can arise before a product is reimbursed.

How the two-step review works under the PMPRB guidelines

StageWhat staff doPossible outcome
Initial or annual reviewCompare the Canadian price with prices in the eleven comparator countries to see if it is the highest; use the CPI to check whether a price increase exceeds inflationNo further action, or referral to in-depth review
In-depth reviewTriggered by a screening concern or a complaint from an approved individual or organization; compare the medicine with similar drugs and treatments for the same conditionsClose the file, or recommend a hearing
HearingA panel of the Board applies s. 85 factorsOrder to reduce price and offset excess revenues, or dismissal

The initial screen is binary: is Canada's price the highest of the comparator countries, and has a price increase outpaced inflation? A medicine that passes both screens and attracts no complaint will normally not be reviewed further. A medicine that fails a screen is not presumed excessive; it moves to an in-depth review in which staff look at therapeutic comparators and the broader context.

Complaints

The new guidelines give complaints a formal role. An in-depth review can begin when an approved individual or organization, such as a public drug plan, files a complaint, even if the screens are passed. Manufacturers should therefore expect public payers to use the complaint mechanism where they consider a price out of line with therapeutic alternatives.

Which medicines the PMPRB guidelines reach

PMPRB jurisdiction is broad. It covers any medicine sold in Canada by a rights holder for an invention that "pertains" to the medicine, which includes patents on the active ingredient, formulations, uses and manufacturing processes, and certificates of supplementary protection. It applies to prescription and non-prescription medicines, brand and generic products, and small molecules and biologics, although the Regulations reduce routine reporting for some categories. For example, where a medicine is not a prescription drug, the rights holder generally files price information only within 30 days after the Board requests it. Veterinary products and medicines sold only for clinical trials raise their own questions.

Jurisdiction ends when the last pertaining patent or certificate expires, but liability for excessive prices charged while patented can survive. Companies should keep a register of every patent that might pertain to each product, including patents owned by licensors and affiliates, because the Board looks at substance rather than corporate form.

Applying the PMPRB guidelines: an illustration

Illustration: a company plans to launch a patented oncology medicine in Canada after launches in the United States, Germany, Japan and the United Kingdom. It proposes a Canadian list price slightly below the German price and above the Japanese and UK prices. Under the initial screen, the key question is whether Canada would be the highest of the eleven comparator countries in which the medicine is sold. If Germany's price is higher, the screen is likely passed. The company then plans annual price increases; each increase is compared with the CPI, and an increase above inflation would trigger closer review.

Two risks remain. First, if the German price falls after a benefit assessment there, Canada could become the highest comparator price without any change in Canada. Second, a provincial drug plan could file a complaint if it considers the price high relative to existing treatments for the same condition, leading to an in-depth review that compares the medicine with those therapies. The company should therefore monitor foreign prices continuously and keep its therapeutic value evidence ready, rather than treating the launch screen as a one-time test.

Hearings and remedies

If an in-depth review suggests that a medicine could be priced excessively, staff may recommend that the Chairperson issue a notice of hearing. A hearing panel then decides whether the price is excessive under s. 85 and what remedy to impose under s. 83. Remedies can include an order to reduce the maximum price and to offset excess revenues by reducing the price of the medicine or another medicine, or by paying an amount to the Crown. Board decisions are subject to judicial review in the Federal Court on the reasonableness standard that generally applies to administrative decisions.

Because hearings are public and can result in significant payments, many issues historically have been resolved through voluntary compliance undertakings with staff, in which the rights holder agrees to adjust its price and offset excess revenues without a hearing. Under the 2026 guidelines, those discussions are likely to focus on the outcome of the in-depth review and the therapeutic comparison.

PMPRB guidelines, pharmacare and provincial listing

PMPRB review is only one step in market access. A medicine's ceiling under the PMPRB guidelines is not the price public plans pay. After Health Canada approval, most new medicines go through health technology assessment by Canada's Drug Agency (formerly CADTH), or INESSS in Quebec, followed by negotiations with the pan-Canadian Pharmaceutical Alliance and listing decisions by each provincial and territorial plan. Negotiated prices are generally confidential and lower than list prices. The federal pharmacare framework legislation enacted in 2024 and related bilateral agreements for specific drug classes add further public purchasing channels.

Health technology assessment bodies and the PMPRB ask different questions. HTA bodies assess clinical and cost-effectiveness and recommend whether, and at what price, public plans should list a medicine. The PMPRB asks only whether the price is excessive under the Patent Act. A medicine can therefore pass the PMPRB screens and still receive a negative or conditional reimbursement recommendation, or the reverse.

The interaction matters strategically. A launch price that sits just below the highest comparator may pass the PMPRB screen but still face long negotiations or a complaint. Manufacturers should plan pricing across these processes together, rather than treating PMPRB compliance as the main constraint.

Compliance steps for manufacturers

  1. Confirm PMPRB jurisdiction for each product, including licensed patents and patents issued after launch.
  2. File introductory and semi-annual price and sales reports on time, with accurate foreign prices for the PMPRB11 countries.
  3. Model the international price screen and planned price increases against the CPI before launch and each year.
  4. Prepare a therapeutic comparison file for each product in case of an in-depth review or complaint.
  5. Coordinate with market access, HTA and pCPA strategy so that positions are consistent.
  6. Monitor PMPRB communications on hearing procedures and further guidance.

Companies acquiring or licensing Canadian rights to patented medicines should also diligence PMPRB filings and any open reviews, since excess revenue liabilities follow the rights holder. Purchase and licence agreements should allocate responsibility for past filings, cooperation in reviews and the cost of any offset ordered under the PMPRB guidelines and the Patent Act.

How TRW & Co helps

We advise pharmaceutical and biotechnology companies and investors on the PMPRB guidelines and patented medicine pricing in Canada. We assess PMPRB jurisdiction, review filing practices, model the 2026 screens, prepare for in-depth reviews and complaints, and support hearing strategy and judicial review alongside Canadian-licensed litigation counsel. We also advise on licensing and acquisition terms that allocate pricing risk. See our life sciences and health page, our patents page and our insights on certificates of supplementary protection and section 6 actions. To discuss a product, contact us. This article is general information, not legal advice.

Frequently asked questions

When did the new PMPRB guidelines take effect?

The PMPRB published new Guidelines for PMPRB Staff on 30 June 2025, and they took effect on 1 January 2026. The Board describes them as departing significantly from previous guidance, with a two-step process of screening and in-depth review.

Which countries are in the PMPRB11?

The schedule to the Patented Medicines Regulations lists Australia, Belgium, France, Germany, Italy, Japan, the Netherlands, Norway, Spain, Sweden and the United Kingdom. Rights holders report prices in these countries, and the initial screen compares the Canadian price with them.

Does the PMPRB set drug prices?

No. It reviews whether prices of patented medicines are excessive. If a hearing panel finds a price excessive under s. 85 of the Patent Act, it can order the price reduced and excess revenues offset. Prices paid by public plans are negotiated separately through the pCPA and provincial listing.

What triggers an in-depth PMPRB review?

An in-depth review begins if the initial screen raises a concern, such as a Canadian price that is the highest among the comparator countries or an increase above inflation, or if an approved individual or organization files a complaint.

What must patentees file with the PMPRB?

Rights holders must report identifying information and prices and sales of the medicine, with an introductory report within 30 days after first sale in Canada and semi-annual reports within 30 days after each January-June and July-December period. Changes to patent information must be reported within 30 days.

Sources

  1. Patent Act, R.S.C. 1985, c. P-4, ss. 79-103
  2. Patented Medicines Regulations, SOR/94-688
  3. PMPRB, PMPRB releases new Guidelines to monitor and review drug prices (June 2025)
  4. PMPRB NEWSletter, Special Edition: New Guidelines (June 2025)

General information only, not legal advice. References to statutes, courts and authorities describe published law and practice at the date shown.